A beneficial deal
31/08/24 -"We have integrated the recent figures, which were broadly in line with our expectations. The positive from the out-licencing of the most advanced pipeline assets (all the mRNA vaccine candidates ..."
Pages
55
Language
English
Published on
31/08/24
You may also be interested by these reports :
17/10/25
The markets were jubilant with Virbac’s Q3 25 beat and a guidance upgrade, especially because the investors, in September 2025, doubted the firm’s ...
06/10/25
Over the week ending 3 October, equity markets delivered another strong performance. In Europe, the STOXX 600 rose 2.9%, driven by a massive rebound ...
03/10/25
We have materially upgraded our earnings estimates for UCB, keeping in view the vigorous uptake of the immunology drug Bimzelx, and a strong support ...
29/09/25
Genmab is strategically acquiring Merus to expand its late-stage portfolio with head and neck cancer treatments, addressing anticipated declines in ...